NEW YORK, May 12, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced the presentation of data supporting a novel mechanism of action for its proprietary drug candidate Metadoxine Extended Release (MDX; MG01CI) at the 69th Annual Scientific Meeting of the Society of Biological Psychiatry (SOBP).1 - See more at: http://www.globenewswire.com/news-release/2014/05/12/635336/10081153/en/Alcobra-Ltd-Presents-Evidence-of-Novel-Mechanism-of-Action-for-Metadoxine-Extended-Release-MDX-in-Cognitive-Disorders-at-the-Society-of-Biological-Psychiatry-Annual-Meeting.html#sthash.zyC2WXTF.dpuf
Help employers find you! Check out all the jobs and post your resume.
